Femoropopliteal Above-Knee Bypass: The True Results
|
|
|
- Carmella Crawford
- 6 years ago
- Views:
Transcription
1 Femoropopliteal Above-Knee Bypass: The True Results Lise Pyndt Jørgensen, Camilla Rasmussen & Torben V Schroeder Rigshospitalet and University of Copenhagen, DENMARK
2 Treatment options in the femoropopliteal segment BMT + Stop smoking and keep walking Bypass surgery Vein in situ, reversed, arm vein etc. Umbilical vein Prosthetic graft PTFE, dacron, Heparin bonded prostetic graft Endovascular options in the SFA segment
3 DeRubertis et al. Ann Surg 2007;246: Percutaneous infra-inguinal revascularization carries a low risk of morbidity and mortality, is well accepted by patients, does not prevent ultimate surgical revascularization if necessary and consequently should be considered the first-line therapy for chronic lower extremity ischemia.
4
5 Factors influencing indication for treating SFA lesions Claudication that interferes with the patient s life Rest pain Ulceration, gangraene
6 Factors influencing choice of treatment Severity of disease Clinical : Claudication vs CLI Anatomical: Lesion length; degree of obstruction; inflow/outflow; TASC TASC II 2007 Increasingly complex disease can be managed using endovascular techniques TASC A: endovascular treatment TASC B & C: can be treated using either TASC D: surgery, owing to endovascular treatment s prohibitive failure rate
7 Factors influencing choice of treatment Severity of disease Clinical : Claudication vs CLI Anatomical: Lesion length; degree of obstruction; inflow/outflow; TASC Risk factors and comorbidities Age, Gender, Smoking, DM, CAD, Lungs, Renal Availability of vein Autologous vein : Always first choice if available Prosthetic grafts The secondary choice above as well as below the knee
8 The immediate answer to The true Fem-Pop results is to look at which graft type produces the best results Searched relevant databases for results of fempop AK from published RCTs on Vein grafts In situ Reversed GSV Prosthetic grafts Human umbilical vein PTFE Dacron Trials on adjuvant procedures left for JB 13 trials were identified : : or newer: 0
9
10 In-situ graft technique vs. reversed greater saphenous vein (GSV) 2 RCT + Cochrane Database Syst Review (Twine et al 2010) Conclusion: no convincing difference
11 Vein (GSV) vs. Prosthetic graft 4 RCT + Cochrane Database Syst Review (Twine et al 2010) Conclusion: Vein better than prosthetic (PTFE) graft
12 Prosthetic graft (PTFE) vs. Human umbilical vein (HUV) 3 RCT : Conclusion: Human umbilical vein better than PTFE
13 Prosthetic grafts: PTFE vs. Dacron 4 RCT + Cochrane Database Syst Review (Twine et al 2010) Conclusion: Dacron is better than PTFE (at 24 and 60 months)
14 The graft material hierachy in the fempop AK position: GSV ~ in situ vein? Human umbilical vein Dacron PTFE
15 Factors influencing choice of treatment Severity of disease Clinical : Claudication vs CLI Anatomical: Lesion length; degree of obstruction; inflow/outflow; TASC I-IV Risk factors and comorbidities Age, Gender, Smoking, DM, CAD, Lungs, Renal Availability of vein Patients perception of disease severity Preference of the patient Preference of the phycisian Availability of endovascular technichnues Ongoing research projects
16 Factors influencing choice of treatment Severity of disease Clinical : Claudication vs CLI Anatomical: Lesion length; degree of obstruction; inflow/outflow; TASC I-IV Risk factors and comorbidities Age, Gender, Smoking, DM, CAD, Lungs, Renal Availability of vein Patients perception of disease severity Preference of the patient Preference of the phycisian Availability of endovascular technichnues Ongoing research projects MIP = Mild Industrial Pressure Economy
17 Which parameters/endpoints are most relevant to compare results obtained with different methods? Seen from the perspective of The patient The physician The society The medical company
18 Which parameters/endpoints are most relevant to compare results obtained with different methods? Seen from the perspective of The patient The physician The society The medical company Patency (pp, sp ) Haemodynamics (flow, ABI, TcPO2 ) Restenosis rate Complications (m&m, stent fractures ) Survival (life, limb, wound) Physical performance (walking distance ) Quality of Life (generic or disease specific ) Economy (patient, society, physician, company )
19 Remember Risk factor modification for every patient. Stop Smoking, Decrease lipid levels, Reduce blood pressure Loose weight, Daily exercise, Better regulation of Diabetes Patients (%) Relative 5-year PAD mortality rates versus other common pathologies Breast cancer Hodgkin's PAD 2 Colon and CLI Lung cancer 1 disease 1 rectal cancer 1 Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) L. Norgren et al. Eur J Vasc Endovasc Surg Vol 33, Supplement 1, 2007 American Cancer Society. Cancer Facts and Figures Kampozinski RF, Bernhard VM. In: Vascular Surgery (Rutherford RB, ed). WB Saunders: 1989;chap 53.
20 Thank You
Evidence-Based Optimal Treatment for SFA Disease
Evidence-Based Optimal Treatment for SFA Disease Endo first Don t burn surgical bridge Don t stent if possible Javairiah Fatima, MD Assistant Professor of Surgery Division of Vascular and Endovascular
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
Disclosures. Objectives. Bypass vs. Endo for SFA Disease: Reaching Consensus on a Rational Approach. Christopher D. Owens, MD 4/23/2009
Disclosures Bypass vs. Endo for SFA Disease: Reaching Consensus on a Rational Approach No disclosures No conflicts of interest Christopher D. Owens, MD Objectives Changing face of our patients presenting
Practical Point in Holistic Diabetic Foot Care 3 March 2016
Diabetic Foot Ulcer : Vascular Management Practical Point in Holistic Diabetic Foot Care 3 March 2016 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report G. Biro, M. Bosiers on behalf of ZILVERPASS Study Group Disclosure Speaker
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia
Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia Traci A. Kimball, MD Department of Surgery Grand Rounds Septemember 13, 2010 Overview Defining Critical Limb Ischemia Epidemiology
Lower Extremity Revascularization D oes Anesthesia Matter. Onaona Gurney PGY 4
Lower Extremity Revascularization D oes Anesthesia Matter Onaona Gurney PGY 4 Case Presentation 89yoM PMH of HTN, DM, HLD, BPH presented to podiatry with abscess to R great toe 5 weeks prior Drained by
Do the newest grafts achieve comparable results to saphenous vein bypass? THE HEPARIN-BONDED eptfe GRAFT. C. Pratesi
Do the newest grafts achieve comparable results to saphenous vein bypass? THE HEPARIN-BONDED eptfe GRAFT C. Pratesi Department of Vascular Surgery University of Florence-Italy www.chirvasc-unifi.it FEMORO-POPLITEAL
Disclosures. In-Stent Restenosis: The Tail IS Wagging the Dog 4/15/2016. Restenosis: The Continuing Challenge for Peripheral Vascular Intervention
In-Stent Restenosis: The Tail IS Wagging the Dog Disclosures NONE Michael S. Conte MD Division of Vascular and Endovascular Surgery UCSF Heart and Vascular Center UCSF Vascular Symposium 2016 IF YOU WERE
DCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
Surgical Bypass vs. Zilver PTX stent for long SFA lesions : Interim results of the ZilverPass Trial
Surgical Bypass vs. Zilver PTX stent for long SFA lesions : Interim results of the ZilverPass Trial Dr. Koen Deloose Head of Vascular Surgery AZ Sint-Blasius Dendermonde Belgium Disclosure slide Speaker
John E. Campbell, MD. Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
3-year results of the OLIVE registry:
3-year results of the OLIVE registry: A prospective multicenter study in patients with critical limb ischemia Osamu Iida, MD Kansai Rosai Hospital Cardiovascular Center Amagasaki, Hyogo, Japan Disclosure
Surgical Bypass or. Zilver PTX. 12 months preliminary data. LINC 2016, Leipzig. Marc Bosiers, MD. Marc Bosiers Koen Deloose Joren Callaert
LINC 2016, Leipzig Surgical Bypass or A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Patrick Peeters Jürgen Verbist Wouter Van den Eynde OLV Hospital,
Practical Point in Diabetic Foot Care 3-4 July 2017
Diabetic Foot Ulcer : Role of Vascular Surgeon Practical Point in Diabetic Foot Care 3-4 July 2017 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai University
Disclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are
An initial strategy of open bypass is better for some CLI patients, and we can define who they are Fadi Saab, MD, FASE, FACC, FSCAI Metro Heart & Vascular Metro Health Hospital, Wyoming, MI Assistant Clinical
Disclosures. TASC, AHA, SVS: What s Happening with the Guidelines? How Are They Relevant? Purpose of Practice Guidelines
TASC, AHA, SVS: What s Happening with the Guidelines? How Are They Relevant? Michael S. Conte MD, FACS Division of Vascular and Endovascular Surgery Co-Director, Heart and Vascular Center UCSF Medical
Endovascular Should Be Considered First Line Therapy
Revascularization of Patients with Critical Limb Ischemia Endovascular Should Be Considered First Line Therapy Michael Conte David Dawson David L. Dawson, MD Revised Presentation Title A Selective Approach
Hybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results.
Hybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results. Wronski J. 1), 2) 3), Wilczynski M 1), Gembal P 1), Milik K 1), Dec St 1), Grybos
Real evidence about coatings, cuffs & other measures to improve above knee synthetic graft patency: What is most effective in comparison with vein?
Real evidence about coatings, cuffs & other measures to improve above knee synthetic graft patency: What is most effective in comparison with vein? Devaraj Srinivasamurthy ESVB 2013 Introduction Significant
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division
Intervention for Lower Extremity PAD: When, why and what?! Robert F Cuff, MD FACS RVT RPVI
Intervention for Lower Extremity PAD: When, why and what?! Robert F Cuff, MD FACS RVT RPVI 1 Disclosures I have no financial disclosures related to this talk Objectives 1. Discuss indications for intervention
Clinical and morphological features of patients who underwent endovascular interventions for lower extremity arterial occlusive diseases
Original paper Clinical and morphological features of patients who underwent endovascular interventions for lower extremity arterial occlusive diseases Sakir Arslan, Isa Oner Yuksel, Erkan Koklu, Goksel
PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014
PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014 Van Crisco, MD, FACC, FSCAI First Coast Heart and Vascular Center, PLLC Jacksonville, FL 678-313-6695 Conflict of Interest Bayer Healthcare
Comparing endoluminal bypass to open fem-pop bypasses; Final 1-year results of the SUPERB trial
Comparing endoluminal bypass to open fem-pop bypasses; Final 1-year results of the SUPERB trial Michel Reijnen Rijnstate Hospital Arnhem, The Netherlands Disclosure Speaker name: Michel Reijnen I have
Stratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI?
Stratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI? Peter F. Lawrence, M.D. Gonda Vascular Center Division of Vascular Surgery
Peripheral Arterial Disease: Who has it and what to do about it?
Peripheral Arterial Disease: Who has it and what to do about it? Seth Krauss, M.D. Alaska Annual Nurse Practitioner Conference September 16, 2011 Scope of the Problem Incidence: 20%
Popliteal Bypass Versus Percutaneous Transluminal
501591SJS102410.1177/1457496913501591The treatment of occlusive superficial femoral artery diseaseh. Linnakoski, et al. 2013 ORIGINAL ARTICLE Scandinavian Journal of Surgery 102: 227 233, 2013 Comparison
4/14/2016. How Far Should We Go with the Endovascular Treatment of Advanced PAD in the Era of Health Care Reform?
FINANCIAL DISCLOSURE How Far Should We Go with the Endovascular Treatment of Advanced PAD in the Era of Health Care Reform? An Endocompetent Vascular Surgeon s View Bruce A. Perler, MD, MBA I Have No Financial
Surgery is and Remains the Gold Standard for Limb-Threatening Ischemia
Surgery is and Remains the Gold Standard for Limb-Threatening Ischemia Albeir Mousa, MD., FACS.,MPH., MBA Professor of Vascular and Endovascular Surgery West Virginia University Disclosure None What you
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
Peripheral Arterial Disease: the growing role of endovascular management
Peripheral Arterial Disease: the growing role of endovascular management Poster No.: C-1931 Congress: ECR 2012 Type: Educational Exhibit Authors: E. M. C. Guedes Pinto, E. Rosado, D. Penha, P. Cabral,
The Final Triumph Of Endovascular Therapy In SFA Treatment
The Final Triumph Of Endovascular Therapy In SFA Treatment MEET 07 Mark W. Mewissen, M.D. Director, St Lukes Vascular Center Milwaukee, WI Endovascular Therapy In SFA Treatment: Works In Progress! Mark
MEET M. Bosiers K. Deloose P. Peeters. SFA stenting in 2009 : The good and the ugly What factors influence patency?
MEET 2009 SFA stenting in 2009 : The good and the ugly What factors influence patency? M. Bosiers K. Deloose P. Peeters 1 TASC II 2007 vs TASC 2000 Type A Type B Type C Type D 2000 < 3 cm 3-5 cm < 3 cm
Diagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC
Diagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC Interventional Cardiologist/Endovascular Specialist Bradenton Cardiology Center Bradenton,
Clinical presentation and outcome after failed infrainguinal endovascular and open revascularization in patients with chronic limb ischemia
From the Society for Clinical Vascular Surgery Clinical presentation and outcome after failed infrainguinal endovascular and open revascularization in patients with chronic limb ischemia Hasan H. Dosluoglu,
North American Society of Cardiovascular Imaging Annual Meeting, Baltimore MD, October 15-18, Tips and Tricks in Vascular Imaging
North American Society of Cardiovascular Imaging Annual Meeting, Baltimore MD, October 15-18, 2016 Tips and Tricks in Vascular Imaging Lower Extremity CTA Dominik Fleischmann, Richard Hallett Division
The incidence of peripheral artery disease (PAD)
Pharmacologic Options for Treating Restenosis The role of cilostazol in the treatment of patients with infrainguinal lesions. By Osamu Iida, MD, and Yoshimitsu Soga, MD The incidence of peripheral artery
SPINACH Making Limb Salvage Salad from Spinach alone
SPINACH Making Limb Salvage Salad from Spinach alone Surgical reconstruction versus Peripheral Intervention in patients with critical limb ischemia prospective multicenter registry in Japan Nobuyoshi Azuma,
Endovascular Is The Way To Go: Revascularize As Many Vessels As You Can
Rafael Malgor, MD Assistant Professor of Surgery The University of Oklahoma, Tulsa Endovascular Is The Way To Go: Revascularize As Many Vessels As You Can Background Lower extremity anatomy (below the
Vasile Goldiş Western University of Arad Faculty of Medicine, Pharmacy and Dental Medicine, Arad, Romania
ENDOVASCULAR TREATMENT FOR VASCULAR GRAFT RESTENOSIS Bogdan Totolici 1, Francisca Blanca Călinescu 1*, Ionel Droc 2, Carmen Neamţu 1 1 Vasile Goldiş Western University of Arad Faculty of Medicine, Pharmacy
4/23/2009. Vein Bypass Remains the Gold Standard AND We Can Improve Outcomes. Lower Extremity Revascularization Options: Key Factors to Consider
Vein Bypass Remains the Gold Standard AND We Can Improve Outcomes Lower Extremity Revascularization Options: Key Factors to Consider General health of the patient Michael S. Conte MD Division of Vascular
Multidisciplinary approach to BTK Y. Gouëffic, MD, PhD
Multidisciplinary approach to BTK Y. Gouëffic, MD, PhD Department of vascular surgery, University Hospital of Nantes, France Response to the increased demand of hospital care Population is aging Diabetes
Extreme SFA Lesions: DETOUR I 12- Month Results in Lesions >30cm. Sean Lyden, MD Chairman Vascular Surgery Cleveland Clinic Cleveland, Ohio
Extreme SFA Lesions: DETOUR I 12- Month Results in Lesions >30cm Sean Lyden, MD Chairman Vascular Surgery Cleveland Clinic Cleveland, Ohio Extreme SFA Lesions: DETOUR I 12-Month Results in Lesions >30cm
Step by step Hybrid procedures in peripheral obstructive disease. Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery
Step by step Hybrid procedures in peripheral obstructive disease Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery Disclosure Speaker name: H.H. Staab I have the following
CRITICAL LIMB ISCHEMIA UNITED STATES EPIDEMIOLOGY TABLE OF CONTENTS
CRITICAL LIMB ISCHEMIA UNITED STATES EPIDEMIOLOGY TABLE OF CONTENTS CRITICAL LIMB ISCHEMIA... 1 CONCLUSION... 9 U.S. CRITICAL LIMB ISCHEMIA PREVALENCE... 9 MARKET OPPORTUNITY ENDOVASCULAR... 9 MARKET OPPORTUNITY
The Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology
The Crack and Pave technique for highly resistant calcified lesions Manuela Matschuck MD University Hospital Leipzig Department Angiology Disclosure Speaker name: Dr. med. Manuela Matschuck I have the
Case Discussion. Disclosures. Critical Limb Ischemia: A Selective Approach to Revascularization Works Best 4/28/2012. None. 58 yo M, DM, CAD, HTN
Critical Limb Ischemia: A Selective Approach to Revascularization Works Best None Disclosures Michael S. Conte MD, FACS Division of Vascular and Endovascular Surgery Co-Director, Heart and Vascular Center
Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015
Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015 Disclosure I have nothing to disclose Randomized Controlled Studies In SFA Technology: What s The Best Tool For
Distal By-Pass procedures can reduce limb loss
Conventional treatment of the diabetic foot Distal By-Pass procedures can reduce limb loss Dr. Nikolaos Melas, PhD Vascular and Endovascular Surgeon Military Doctor Associate in 1st department of Surgery,
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
PROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Drug-eluting balloon angioplasty versus non-stenting balloon angioplasty for peripheral arterial disease of the lower limbs [Cochrane Protocol]
Treatment Strategies For Patients with Peripheral Artery Disease
Treatment Strategies For Patients with Peripheral Artery Disease Presented by Schuyler Jones, MD Duke University Medical Center & Duke Clinical Research Institute AHRQ Comparative Effectiveness Review
Does heparin impregnated graft improve patency and reduce the cost of lower limb bypass? The REPLACE trial Y. Gouëffic, MD, PhD
Does heparin impregnated graft improve patency and reduce the cost of lower limb bypass? The REPLACE trial Y. Gouëffic, MD, PhD Department of vascular surgery, University hospital of Nantes, France Disclosure
Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results
Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results Hiroyoshi Yokoi, MD, Fukuoka Sannou Hospital Fukuoka, Japan On behalf
Objective assessment of CLI patients Hemodynamic parameters
Objective assessment of CLI patients Hemodynamic parameters Worth anything in end stage patients? Marianne Brodmann Angiology, Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann
Hybrid Procedures for Peripheral Obstructive Disease - Step by Step -
Hybrid Procedures for Peripheral Obstructive Disease - Step by Step - Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery Disclosure Speaker name:..holger Staab... I have
LIMB SALVAGE IN THE DIABETIC PATIENT
LIMB SALVAGE IN THE DIABETIC PATIENT WHO? HOW? BEST? DISCLOSURES Educational grant from Cook Inc OBJECTIVES Review risk stratification and staging schemes for the threatened limb Discuss current concepts
PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler Jones, MD September 14, 2016
PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler, MD September 14, 2016 Interventional Cardiology and Cath Labs Disclosures Research Grants: Agency for Healthcare Research
Managing Conditions Resulting from Untreated Cardiometabolic Syndrome
Managing Conditions Resulting from Untreated Cardiometabolic Syndrome Matthew P. Namanny DO, FACOS Vascular/Endovascular Surgery Saguaro Surgical/AZ Vascular Specialist Tucson Medical Center Critical Limb
Critical Limb Ischemia A Collaborative Approach to Patient Care. Christopher LeSar, MD Vascular Institute of Chattanooga July 28, 2017
Critical Limb Ischemia A Collaborative Approach to Patient Care Christopher LeSar, MD Vascular Institute of Chattanooga July 28, 2017 Surgeons idea Surgeons idea represents the final stage of peripheral
Current Vascular and Endovascular Management in Diabetic Vasculopathy
Current Vascular and Endovascular Management in Diabetic Vasculopathy Yang-Jin Park Associate professor Vascular Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine Peripheral artery
Peripheral arterial disease for primary care Ed Aboian, MD
Peripheral arterial disease for primary care Ed Aboian, MD Division of Vascular and Endovascular Surgery Palo Alto Medical Foundation, Burlingame Ca Disclosures Nothing to disclose Clinical presentation
Lower Extremity Peripheral Arterial Disease: Less is Sometimes More. Spence M Taylor, M.D.
Lower Extremity Peripheral Arterial Disease: Less is Sometimes More Spence M Taylor, M.D. President, Greenville Health System Clinical University Senior Associate Dean for Academic Affairs and Diversity
Early Identification of PAD: Evidence to Refute USPSTF Position on Screening
Early Identification of PAD: Evidence to Refute USPSTF Position on Screening Mehdi H. Shishehbor, DO, MPH, PhD Director Endovascular Services Interventional Cardiology & Vascular Medicine Department of
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
9/7/2018. Disclosures. CV and Limb Events in PAD. Challenges to Revascularization. Challenges. Answering the Challenge
Disclosures State-of-the-Art Endovascular Lower Extremity Revascularization Promotional Speaker Jansen Pharmaceutical Promotional Speaker Amgen Pharmaceutical C. Michael Brown, MD, FACC al Cardiology Associate
Atherectomy with thrombectomy of. Rotarex S : The Leipzig experience
Atherectomy with thrombectomy of femoropopliteal occlusions with Rotarex S : The Leipzig experience Dr. Bruno Freitas, Prof., MD Department of Interventional Angiology, Universität Leipzig, Germany Santa
Registry Assessment of Peripheral Interventional Devices (RAPID)
Registry Assessment of Peripheral Interventional Devices (RAPID) Adding Data Sources May 2, 2018 W. Schuyler Jones, MD Duke Clinical Research Institute Duke Heart Center Disclosures Research Grants: Agency
Interventional Treatment First for CLI
Interventional Treatment First for CLI Patrick Alexander, MD, FACC, FSCAI Interventional Cardiology Medical Director, Critical Limb Clinic Providence Heart Institute, Southfield MI 48075 Disclosures Consultant
Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Distal hybrids - an option in long SFA CTO accompanied by severely compromized crural runoff
Distal hybrids - an option in long SFA CTO accompanied by severely compromized crural runoff P. Kuryanov, A. Lipin, A. Antropov, K. Atmadzas, A. Atmadzas, Y. Eminov, A. Borisov, R. Sobolev, A.Orlov Limb
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis Osamu Iida, MD From the Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan. ABSTRACT: Approximately
DCB level 1 evidence review
DCB level 1 evidence review Raphaël COSCAS Vascular Surgery Department Ambroise Paré Hospital, AP-HP and Paris-Ouest University Boulogne-Billancourt, France Disclosure Speaker name: Raphael COSCAS I have
Remote Endarterectomy Update
Remote Endarterectomy Update An endovascular alternative to bypass? BY JOHN D. MARTIN, MD Treating the superficial femoral artery (SFA) is still one of the most highly debated topics among vascular specialists.
RAPID Phase III Perspectives from the Medical Device Industry
RAPID Phase III Perspectives from the Medical Device Industry Megan M. Brandt Vice President, Quality and Regulatory Affairs Cardiovascular Systems, Inc. St. Paul, MN PAD and Critical Limb Ischemia: Disease
Larry Diaz, MD, FSCAI Mehdi H. Shishehbor, DO, FSCAI
PAD Diagnosis Larry Diaz, MD, FSCAI Metro Health / University of Michigan Health, Wyoming, MI Mehdi H. Shishehbor, DO, FSCAI University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH PAD:
The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
Surgical Options for revascularisation P E T E R S U B R A M A N I A M
Surgical Options for revascularisation P E T E R S U B R A M A N I A M The goal Treat pain Heal ulcer Preserve limb Preserve life The options Conservative Endovascular Surgical bypass Primary amputation
Hypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
Medical therapy after angioplasty / stenting
Nurse and Technician Forum Part I Medical therapy after angioplasty / stenting Erich Minar Department Angiology Medical University Vienna Disclosure Speaker name: Erich Minar I do not have any potential
IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of
IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of referenced technologies as well as current standards of care
The Struggle to Manage Stroke, Aneurysm and PAD
The Struggle to Manage Stroke, Aneurysm and PAD In this article, Dr. Salvian examines the management of peripheral arterial disease, aortic aneurysmal disease and cerebrovascular disease from symptomatology
LIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:
LIBERTY 360 Study LIBERTY is a prospective, observational, multi-center study to evaluate procedural and long-term clinical and economic outcomes of endovascular device interventions in patients with symptomatic
Forget about the angiosome theories. Yann Gouëffic, MD, PhD Department of vascular surgery, institut du thorax, Nantes, France
Forget about the angiosome theories Yann Gouëffic, MD, PhD Department of vascular surgery, institut du thorax, Nantes, France Disclosure of Interest Research grants /Consulting/Honoraria for - Abbott -
Endovascular treatment of severe TASC C and D external iliac artery occlusive disease. SAINT-LEBES Bertrand Toulouse FRANCE
Endovascular treatment of severe TASC C and D external iliac artery occlusive disease SAINT-LEBES Bertrand Toulouse FRANCE Disclosure Speaker name: SAINT-LEBES I have the following potential conflicts
Popliteal Aneurysm: When is surgical therapy indicated? PROF. GRZEGORZ OSZKINIS
Popliteal Aneurysm: When is surgical therapy indicated? PROF. GRZEGORZ OSZKINIS Asymptomatic mass - 38-40%will develop symptoms at a rate of 14%/yr Intermittent claudic ation (chronic ischemia) - 25%-40%
Drug-Eluting Balloon Angioplasty versus Bare Metal Stents for Femoropopliteal Disease in Real-World Experience
Drug-Eluting Balloon Angioplasty versus Bare Metal Stents for Femoropopliteal Disease in Real-World Experience Maria Doyle, M.Eng; Hilary Coffey, M.D. Ravindra Gullipalli, MBBS, FRCR St. Clare s Mercy
Peripheral Vascular Disease
Peripheral artery disease (PAD) results from the buildup of plaque (atherosclerosis) in the arteries of the legs. For people with PAD, symptoms may be mild, requiring no treatment except modification of
Clinical Approach to CLI and Related Diagnostics: What You Need to Know
Clinical Approach to CLI and Related Diagnostics: What You Need to Know Ido Weinberg, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital None Disclosures Critical
How Do We Optimize the Medical Therapy of Patients with Critical Limb Ischemia?
How Do We Optimize the Medical Therapy of Patients with Critical Limb Ischemia? Ehrin J. Armstrong, MD MSc MAS Director, Interventional Cardiology Director, Vascular Laboratory VA Eastern Colorado Healthcare
Disclosures. Carotid artery stenting. Surveillance after Endovascular Intervention: When to Re-Intervene and What s the Evidence
Disclosures Surveillance after Endovascular Intervention: When to Re-Intervene and What s the Evidence None 2015 UCSF Vascular Symposium Warren Gasper, MD Assistant Professor of Surgery UCSF Division of
PERIPHERAL CTA. Richard L. Hallett, MD
RC 812B Lakeside E351 1 December 2017 0830 1000 Richard L. Hallett, MD Chief, Cardiovascular Imaging Northwest Radiology Network Indianapolis, IN Adjunct Assistant Professor Radiology Cardiovascular Imaging
Photoablation and DCB in in-stent restenosis
Photoablation and DCB in in-stent restenosis Craig M. Walker, MD, FACC, FACP Clinical Professor of Medicine Tulane University School of Medicine New Orleans, LA Clinical Professor of Medicine LSU School
Abstract. Key words: peripheral artery disease, lower limb, endovascular therapy, Iran
The evaluation of the success rate, complications and midterm follow up results of patients with peripheral arterial disease of lower limb treated using endovascular therapy: A single center study Mohammad